A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Adding ezetimibe (Zetia) therapy to statins early after a heart attack improved outcomes, Swedish national records suggested.

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...